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1
Introduction
This study is carried out to see whether the different treatment effects
does different impact or not in the increment and the decrement of viruses
under the given time period, i.e., the treatments, that have been applied,
make any sense in the increment and the decrement of these viruses? or is
there any influence of the treatments on the virus?. If there seem differences
on the increment and the decrement of viruses for the given treatment effects
in the given time period then the study is conducted to analyse whether
these apparent differences are statistically significant or not. In other words,
this study is carried out to get the conclusion about the statement: “Is
there any significant difference between the treatments?”. In our study, the
experimental data is taken for 25 days [J.B. Larsen, A. Larsen, R. Thyrhaug,
G. Bratbak and R.-A. Sandaa, 9 April 2008], in which three different fixed
types of treatments are applied on the different batches of virus and three
randomly choosen such batches are treated under the each of the treatments.
So, there are nine different random groups of virus such that each of three
random groups are treated under only one particular fixed treatement, i.e.,
each one treatment has only three random groups. So, there are nine random
groups for three different fixed treatment effects. This experiment has a
balanced data set as each unique treatment has three replications and within
each replication, the data is observed for 25 days . In this study, these
random groups are known as the meso groups. Hence, the main purpose
of this study is to know if those applied three treatments are statistically
significant or not. It has been assumed that the experiment is conducted
under the same circumstances for all the parallel mesos.
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Figure 1.1: Plot of the given dataset with respect to numbers of viruses
versus time period for the three different treatments
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Figure 1.1 is the plot of the given dataset for three fixed treatment effects
for 25 days of time period. We can see that at the begining of the experiment,
there is no such a noticeable increment or decrement of viruses in all three
treatments. Whereas at the middle of the experiment, there starts some
rapid increment of viruses with seemingly different level of intensities for all
three different treatments and, it increases gradually and reaches some upper
level of increment and maintains this level approximately to the end of the
time period. In the figure, it seems that the levels of increments differ by the
treatment. There also seems that the rapid increment seems to start earlier
in the treatment C than in the treatment A and B. And the steepness of the
increment curves for all mesos in the treatment A seems to be lower than in
the treatment B and C with respect to the time period.
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Figure 1.2: Plot of the meso groups variability within the three different
treatments with respect to the time period, when k > 15
Our study concentrates on whether these apparent differences, that is,
the increment of virus growth because of the different treatment effects,
are statistically significant or not. For this purpose we begin our study
by analyzing the data taken after some days of the experiment beginning.
Since at the beginning of the experiment, there seem no differences in the
growth of virus in all three treatments. But at the end of the experiment,
there seem to be larger differences in the data points and the levels of the
increment are also seemed to be different for different treatments. The Figure
3
1.2, plotted after day 15, shows the difference in the increment of virus in
different treatments. That is, in all three treatments the variability of data
points increase with the increment of the virus growth where all three meso
groups in the treatment A have the lower upper level than in the treatment
B and C, i.e., in average, treatment A has the lowest virus increment level
among these three treatments. There, also seems to be some variability
in data points within all treatments and these variability of data points are
comparatively higher in the treatment B than in the treatments A and C. So,
the treatment B has more scattered data points at the upper right part of the
curve. However, in our study, we mainly focus on the effects of treatments
on the average virus increment level rather than to see the individual within
variability of the meso groups within each treatment. So, we further analysis
if these different levels of increment of viruses for different treatments are
statistically significant or not.
4
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Preparation for the analysis
In our study, let us denote the three fixed treatments A, B, and C by
i = 1, 2, and 3 respectively, the random meso groups by j = 1, 2, · · · , 9
(Here, for i = 1, j = 1, 2, 3; for i = 2, j = 4, 5, 6; for i = 3, j = 7, 8, 9) and,
the time period by k = 1, 2, 3, · · · , 25. Hence, the response variable, Yijk
is kth day’s observation of the jth meso group for the ith treatment, i.e.,
each observation is nested under the particular meso group and these meso
groups are nested within the particular treatment. Such type of experiment
is known as Nested design. Since in our study, three different treatment
effects appear as the fixed effect and the nine meso random groups appear
as the random effect, the study is combination of both fixed and random
effects. So, it is also known as Mixed Effects Model. In figure 1.1, we have
seen that there is the highest level of average increment of the viruses in the
treatment C and also, there is a lot of variation between the meso groups
under the same treatment. But our main concern is to study the treatment
effects on these viruses. So, when we plot the data set after a certain time
period, say, k > 15, figure 2.1, gives an approximately the last part of data
curve of our study which clearly visualizes the differences among the upper
level of increment of viruses in the three different treatments. Where the
treatment C has the highest level of average increment of viruses among
three treatment effects which is also above the average level of the grand
mean (for k > 15) of the data set. The treatment A has the lowest average
increment of virus, i.e., the average level of a treatment A is below the
grand mean whereas the average of treatment B has the level approximately
near the grand mean.
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Figure 2.1: Plot of the dataset when k > 15 for three different
treatments
There also seems that the within variability of data points is higher in
the treatment B, that is, the highest scattered data points are seemed in the
treatment B. These types of variability within each treatment and between
treatments arise due to the cause of various factors. But, in our study, we
mainly focus on only one cause factor, i.e., the treatment effect. Therefore,
we apply an appropriate statistical technique to analyse if these different
upper part differences arise due to the different treatment effects or not.
Generally, we apply t-test to test the significance of the difference between
two group means. But in our case, there are three treatments and in such
type of cases, a test is done by the analysis of variance, abbreviated by
ANOVA, concerned with analyzing variation in means. An analysis of vari-
ance refers to an additive decomposition of data into a grand mean, main
effects, possible interactions and an error term [Gelman, 2005].
6
3
Analysis of Variance
The great British statistician R. A. Fisher developed the analysis of
variance method in the 1920s. The main objective of this technique is a
significance test, using his F distribution, for detecting differences among a
set of population means. F-Statistic is defined as the ratio of two indepen-
dent chi-square variates divided by their respective degrees of freedom and
it follows Snedecor’s F−distribution with (ν1, ν2) degree of freedom with
probability function given by
f(x|ν1, ν2) =
Γ(ν1+ν22 )
Γ(ν12 )Γ(
ν2
2 )
(
ν1
2
)ν1/2
x(ν1−2)/2
(1 + ν1ν2x)
(ν1+ν2)/2
0 ≤ x ≤ ∞
The analysis of variance (ANOVA) is an F-test of a null hypothesis that there
is no significant difference between all the treatments against an alternative
hypothesis that there is at least two of the treatment means are unequal.
Variation is inherent in nature. The total variation in any set of numerical
data is due to a number of causes which may be classified as:
(i) Assignable causes, and (ii) Chance causes.
The variation due to assignable causes can be detected and measured whereas
the variation due to chance causes is beyond the control of human hand and
can not be traced separately. For the validity of the F−test in ANOVA, the
following assumptions are made:
• The observations are independent (independence).
• The variance is the same for all observations (homogeneous variance).
• Parent population from which observations are taken is normal (nor-
7
mality), and
• Various treatment and environmental effects are additive in nature.
[S. C. Gupta and V. K. Kapoor, 1994]. Researchers use ANOVA in many
ways. Generally, reseachers use ANOVA in three ways: one-way ANOVA,
two-way ANOVA and N-way multivariate ANOVA [Dr. James, 1996-2011].
Since in our study, we are mainly concern with the treatments effects only,
so we focus on one-way anova in this study.
3.1 One way ANOVA
Let I denotes the number of treatments (or classes) to be compared.
The means of the response variable for the corresponding treatments are
µ1, µ2, µ3, · · ·µI . Mathematically, we write
H0 : µ1 = µ2 = · · · = µI ; i = 1, · · · , I
against
H1 : µi 6= µj for some i, j
If H0 is false, there may be all the treatment means are differ, may be some
differ, or may be merely one mean differs from the others. The test analyzes
whether the differences observed among the treatment means could have
reasonably occured by chance, if H0 were true.
In our study, we are interested to see whether there is significant differ-
ence between the treatment effects or not. We try to define a simple model
by decomposing the response variable into the following two components:
• The variation between the treatments (or the classes), i.e., the varia-
tion due to different types of treatments.
• The variation within the treatments, i.e., the inherent variation of the
response variable within the treatments.
The first type of variation is due to assignable causes, also known as treat-
ment effects, which can be detected and controlled by human endeavour and
the second type of variation is due to chance causes, also known as errors or
8
residuals, which are beyond the control of human hand. So the sources of
variation are
• Effect of the treatment
• Error ε produced by numerous causes of such magnitude that they are
not detected and identified with the knowledge that we have and they
together produce a variation of random nature obeying Normal law of
errors.
3.2 Mathematical Model
In this case the linear mathematical model will be
Yijk = µi + εijk
= µ+ (µi − µ) + εijk
= µ+ αi + εijk (3.1)
where (i = 1, 2, · · · , I; j = 1, 2, · · · , J ; k = 1, 2, · · · , k)
• Yijk is the response variable (i.e., the number of virus in our study)
from the kth day of the jth meso batch for the ith treatment.
• µ is the general mean effect given by
µ = JK
I∑
i=1
µi/IJK
where µi is the fixed effect due to the ith treatment i.e. if there were
no treatment differences and no chance causes then the output of the
response will be µ.
• αi is the effect of the ith treatment given by αi = µi−µ, (i = 1, 2, · · · I),
i.e., the ith treatment increases or decreases the output of response by
an amount αi and we get,
JK
I∑
i=1
αi =JK
I∑
i=1
(µi − µ)
=JK
I∑
i=1
µi − IJKµ = Nµ−Nµ .
9
where IJK = N, the total number of observations.
JK
I∑
i=1
αi = 0.
• εijk is the error effect due to chance.
3.2.1 Assumptions in the Model
• Population from which observations are taken is normal.
• The variance of the population distribution is homogenous for all treat-
ments.
• The error terms are independent and normal i.e. ε ∼ N(0, σ2)
under the third assumption, the model (3.1) becomes as
E(Yijk) = µi = µ+ αi
[S. C. Gupta and V. K. Kapoor, 1994].
3.3 Statistical Analysis of the Model (3.1)
When the assumptions of the ANOVA fullfills, then we use an ANOVA
test. Let us write
Y¯··· = overall mean =
∑I
i=1
∑J
j=1
∑K
k=1 Yijk
IJK
and Y¯i·· = mean of the ith treatment =
∑J
j=1
∑K
k=1 Yijk
JK
The parameters µ and αi in model (3.1) are estimated by the principle of
least squares on minimizing the error sum of squares given by
E =
I∑
i=1
J∑
j=1
K∑
k=1
ε2ijk =
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − µ− αi)2 = 0
10
The normal equations for estimating µ and αi are
∂E
∂µ
= −2
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − µ− αi) = 0 (3.2)
and
∂E
∂αi
= −2
J∑
j=1
K∑
k=1
(Yijk − µ− αi) = 0 (3.3)
From equation (3.2), we get
∑
i=1
J∑
j=1
K∑
k=1
Yijk −Nµ− JK
I∑
i=1
αi = 0
µˆ =
∑J
j=1
∑K
k=1 Yijk
N
= Y¯··· (3.4)
From equation (3.3), we get
J∑
j=1
K∑
k=1
Yijk − JKµˆ− JKαˆi = 0
αˆi =
1
JK
J∑
j=1
K∑
k=1
Yijk − µˆ = Y¯i·· − µˆ
αˆi = Y¯i·· − Y¯··· (3.5)
and, substituting above values in (3.1), we get
Yijk = Y¯··· + Y¯i·· − Y¯··· + εijk
Yijk − Y¯··· = Y¯i·· − Y¯··· + εijk
To balance the L.H.S and R.H.S, we introduce εijk = Yijk − Y¯i·· such that
Yijk − Y¯··· = Y¯i·· − Y¯··· + Yijk − Y¯i··
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯···)2 =
I∑
i=1
J∑
j=1
K∑
k=1
(Y¯i·· − Y¯··· + Yijk − Y¯i··)2
11
But, we know,
∑I
i=1
∑J
j=1
∑K
k=1(Yijk − Y¯i··) = 0.
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯···)2 = JK
I∑
i=1
(Y¯i·· − Y¯···)2 +
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯i··)2
But,
∑I
i=1
∑J
j=1
∑K
k=1(Yijk − Y¯i··) = 0, since the algebric sum of the devia-
tions of the treatments from their mean is always zero.
TSS = SSB + SSW
where,
TSS = Total Sum of Squares which measures the total variability in the dataset.
SSB = Between Sum of Squares which measures the variation between the
different treatments
SSW = Error Sum of Squares or Within Sum of Squares which meaures the
variation between the response variables under the particular given treatment.
Hence, the total sum of squares (TSS) is the sum of treatment sum of squares
(SSB) and error sum of squares (SSW ).
Here, we have,
Yijk = µ+ αi + εijk
Y¯i·· = µ+ αi + ε¯i··
then
Yijk − Y¯i·· = εijk − ε¯i··
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯i··)2 =
I∑
i=1
J∑
j=1
K∑
k=1
(εijk − ε¯i··)2
SSW =
I∑
i=1
J∑
j=1
K∑
k=1
(εijk − ε¯i··)2
E(SSW ) =
I∑
i=1
E[
J∑
j=1
K∑
k=1
(εijk − ε¯i··)2]
12
E(SSW ) =
I∑
i=1
(JK − 1)σ2
= I(JK − 1)σ2
σˆ2 =
SSW
I(JK − 1)
also,
Yijk = µ+ αi + εijk
Y¯i·· = µ+ αi + ε¯i··
Y¯··· = µ+ α¯+ ε¯···
Y¯i·· − Y¯··· = αi − α¯+ ε¯i·· − ε¯···
I∑
i=1
J∑
j=1
K∑
k=1
(Y¯i·· − Y¯···)2 =
I∑
i=1
J∑
j=1
K∑
k=1
(αi − α¯+ ε¯i·· − ε¯···)2
SSB = JK[
I∑
i=1
(αi − α¯)2 + (ε¯i·· − ε¯···)2
+ 2(αi − α¯)(ε¯i·· − ε¯···)]
E(SSB) = JK[E[
I∑
i=1
(αi − α¯)2 + (ε¯i·· − ε¯···)2]]
Since E(ε¯i·· − ε¯···) = 0
E(SSB) = JK[E[
I∑
i=1
(ε¯i·· − ε¯···)2]] + JK[
I∑
i=1
(αi − α¯)2]
E(SSB) = (A) + (B)
while considering part (A), we have
εijk ∼ N(0, σ2)⇒ ε¯i·· ∼ N(0, σ2/JK)
and when Xi ∼ N(0, τ2) ⇒ E[
∑I
i=1(Xi − X¯)2] = (I − 1)τ2
So, JK[E[
I∑
i=1
(ε¯i·· − ε¯···)2]] = JK(I − 1) σ
2
JK
13
(A) = (I − 1)σ2
Therefore,
E(SSB) = (I − 1)σ2 + JK[
I∑
i=1
(αi − α¯)2]
We know, under H0 : µ1 = µ2 = · · · = µI = 0⇒ H0 : α1 = α2 = · · · = αI =
0. So, we have
E(SSB) = (I − 1)σ2
E[SSB/(I − 1)] = σ2
σˆ2 =
SSB
(I − 1) ≡
SSW
I(JK − 1)
but, under H1 not all αi’s are 0⇔ not all µi’s are equal. So,
E[
SSB
(I − 1) ] = σ
2 +
JK
I − 1
I∑
i=0
(αi − α¯)2
= σ2 +
JK
I − 1ϕ(α)
[ Since ϕ(α) =
I∑
i=1
(αi − α¯)2 ].
we know, the F− ratio is defined as,
F =
SSB/(I − 1)
SSW/I(JK − 1)
Since, under H0,
E[SSB/(I − 1)] = σ2 and,
E[SSW/I(JK − 1)] = σ2
F =
SSB/(I − 1)
SSW/I(JK − 1) ≈ 1.
⇒ F − ratio around 1 under the H0.
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But, when H0 is wrong, we have
E[SSB/(I − 1)] = [σ2 + JK
I − 1ϕ(α)] > σ
2 and,
E[SSW/I(JK − 1)] = σ2
therefore,
F =
SSB/(I − 1)
SSW/I(JK − 1) such that
E(SSB/I − 1)
E(SSW/I(JK − 1)) > 1, under H1.
⇒ F − ratio tending to be large under H1.
where (I−1) and I(JK−1) are the degrees of freedom for sum of squares due
to treatment effects and sum of squares due to the error term respectively.
3.4 Kruskal-Wallis Test
The Kruskal-Wallis test is a nonparametric (distribution free) test, which
is used to compare three or more groups of sample data. This test is used
when assumptions of ANOVA are not met. ANOVA is a statistical data
analysis technique that is used when the independent variable groups are
more than two. In ANOVA, we assume that distribution of each group
should be normally distributed. But in the Kruskal-Wallis test, we have the
following assumptions.
3.4.1 Assumptions
• The observations are not necessarily normally distributed.
• The observations in each group come from populations with the same
shape of distribution but possibly shifted with respect to each other.
[McDonald, 2009]. If different groups have have different shapes (one is
skewed to the right and another is skewed to the left, for example, or they
have different variances), the Kruskal–Wallis test may give inaccurate results
[Morten W. Fagerland, 10 May 2009]. If normality assumptions are met, then
the Kruskal-Wallis Test is not as powerful as ANOVA [Dr. James, 1996-
2011]. However, these distributions should be continuous and have identical
form [Green and Salkind, 2008].
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3.4.2 Hypothesis
Null hypothesis (H0): Null hypothesis assumes that the distributions are
from identical populations.
Alternative hypothesis (H1): Alternative hypothesis assumes that the
distributions are shifted with respect to each other.
In this test, the following assumptions are made:
• The samples drawn from the population are random.
• The treatments are independent.
• The measurement scale for should be at least ordinal.
3.4.3 Procedure
• Arrange the data of all samples in a single series in ascending order.
• Assign rank to them in ascending order. In the case of a repeated
value, assign ranks to them by averaging their rank position.
• Once this is complete, ranks of the different samples are separated and
summed up as R1, R2, R3 etc [Dr. James, 1996-2011].
• To calculate the value, apply the following formula:
H =
12
N(N + 1)
(
I∑
i=1
R2i
ni
)− 3(N + 1)
Where,
H = Kruskal-Wallis Test Statistic
N = total number of observations in all samples
Ri = Sum of the rank observation for group i and ni is the number of
observation in group i [Lowery, 1999-2011].
• Finally, The null hypothesis of equal population medians would then
be rejected if H ≥ χ2(α,I−1). Appropriate multiple comparisons would
then be performed on the group medians [Wikipedia/Kruskal].
In our case, we have 3 treatment groups and, for each treatment group, we
have 30 observations. So, χ2(.05,2) = 5.991
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Treatment Ri ni
A 583.5 30
B 1310 30
B 2201.5 30
N = 90
Table 3.1: Rank totals for three treatments
Hence, we get, the Kruskal-Wallis test statistic (H) = 64.15, i.e, the
calculated test statistics is greater than the tabulated test statistic at 5 %
level of significane. Therefore, we reject the null hypothesis. That is, the
distributions are not from identical populations.
3.5 Traditional one way anova table
Source of Degree Sum of Mean Squares F-value p-value
variation of freedom Squares
Treatments (I − 1) SSB SSB/(I − 1) MSBMSE
Residuals (N − I) SSE SSE/(N − I)
Total (N − 1) TSS
Table 3.2: Traditional one-way ANOVA source table
The p-value gives the statistical significance of the F-ratio with reference
to the F(ν1,ν2), where ν1 and ν2 are the numerator and denominator degrees
of freedom, respectively [Gelman, 2005].
Now, when we use the given dataset for K > 15 in a model (3.1), we
have
Yijk = µ+ αi + εijk
where,
i = 1, 2, 3; j = 1, 2, · · · , 9; k = 16, 17, · · · , 25
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µ = The grand mean for all data points, after day 15.
α1 = Effects of the treatment A.
α2 = Effects of the treatment B.
α3 = Effects of the treatment C.
Then, by using the lm function, we get the following estimates of the average
for treatment A, B and C respectively :
Treatment A Treatment B Treatment C
Estimates (µˆi) 74.40× 104 114.76× 104 176.60× 104
Table 3.3: Estimates of treatments.
and the corresponding ANOVA table is given by,
Response DF Sum Squares Mean Squares F-value p-value
Treatment 2 15.7× 1012 78.50× 1011 128.74 < 2.2e−16
Residuals 87 53.05× 1011 60.98× 109
Table 3.4: Traditional One-way ANOVA table for k > 15
Residual standard error: 246900 on 87 degrees of freedom.
i.e. σˆ2 = 60.98× 109
Because of the small p− value and the calculated F(2,87) = 128.74 which is
greater than the tabulated F(2,87)(.05), made us to conclude that there is
significant difference between the treatment effects.
Here, for the model (3.1), the assumption of independence of errors is not
satisfied because within each meso the observations are not independent.
Their correlation is larger for observations coming from the same meso than
for two observations coming from different mesos. So, we try to define an-
other model by treating the meso group effect as a random effect which is
known as the mixed effects model.
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4
Mixed Effects Model
Now, we try to change the model (3.1) to motivate the random effects
model in our dataset for k > 15. We write
Yijk = µ+ αi + bij + εijk (4.1)
for i = 1, j = 1, 2, 3; for i = 2, j = 4, 5, 6; for i = 3, j = 7, 8, 9
and, k = 16, 17, · · · , 25
where, µ is the overall mean for the entire treatments, i.e., the grand mean,
αi is a fixed variable representing the deviation from the grand mean for the
ith treatment, bij is a random variable representing the effect of jth meso
group on the treatment i and, εijk is a random variable representing the
deviation of a response variable for kth day of meso group j on treatment i
from the mean effect of treatment i. To be a statistical model, the distribu-
tion of the random variables bij and εijk must be specified. We assume both
of these variables are independent and normally distributed with mean zero
and variances τ2 and σ2 respectively. That is,
bij ∼ N(0, τ2), εijk ∼ N(0, σ2)
Where bij ’s are called random effects because they are incorporated with
the particular experimental units − mesos in our case − that are selected
from the population of interest. They are effects because they represent a
deviation from the treatment mean. That is, the “effect" of the treatment
i is to shift from the treatment mean µ + αi to µ + αi + bij [Pinheiro and
Bates, 2000]. Since the model (4.1) has both fixed and random effects, it is
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known as Mixed Effects model or Mixed model.
4.1 Statistical Analysis of the Model (4.1)
When the above mentioned assumptions are fullfilled, then we can write
Y¯··· = overall mean =
∑I
i=1
∑J
j=1
∑K
k=1 Yijk
IJK
Y¯i·· = mean of the ith treatment =
∑J
j=1
∑K
k=1 Yijk
JK
and,
Y¯ij· = mean of the jth meso for the treatment i =
∑K
k=1 Yijk
K
The parameters µ, τ2 and σ2 in model (4.1) are estimated by the principle
of least squares on minimizing the error sum of squares given by
E =
I∑
i=1
J∑
j=1
K∑
k=1
ε2ijk =
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − µ− αi − bij)2 = 0
Proceeding the similar way as described in the model (3.1), after solving the
normal equations, we get
µˆ =
∑J
j=1
∑K
k=1 Yijk
N
= Y¯··· (4.2)
αˆi =
1
JK
J∑
j=1
K∑
k=1
Yijk − µˆ = Y¯i·· − Y¯··· (4.3)
bˆij =
1
K
K∑
k=1
Yijk − 1
JK
J∑
j=1
K∑
k=1
Yijk = Y¯ij· − Y¯i··
(4.4)
and, substituting above values in (4.1), we get
Yijk − Y¯··· = (Y¯i·· − Y¯··· + Y¯ij· − Y¯i·· + Yijk − Y¯ij·)
We introduce the error term εijk so that both the sides are equal.
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯···)2 =
I∑
i=1
J∑
j=1
K∑
k=1
(Y¯i·· − Y¯··· + Y¯ij· − Y¯i·· + Yijk − Y¯ij·)2
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I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯···)2 =JK
I∑
i=1
(Y¯i·· − Y¯···)2 +K
I∑
i=1
J∑
j=1
(Y¯ij· − Y¯i··)2
+
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯ij·)2
Here, the product terms disappear because the set up is balanced.
TSS = SSB + SSR+ SSW
Where,
TSS =
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯···)2 = Total sum of squares.
SSB =JK
I∑
i=1
(Y¯i·· − Y¯···)2 = Sum of squares due to the treatments
SSR =K
I∑
i=1
J∑
j=1
(Y¯ij· − Y¯i··)2 = Sum of squares due to random meso groups.
SSW =
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯ij·)2 = Sum of squares due to error terms.
Now, We know the model (4.1) is
Yijk = µ+ αi + bij + εijk (4.5)
Y¯ij· = µ+ αi + bij + ε¯ij· (4.6)
Subtracting equation (4.6) from equation (4.5), we get
(Yijk − Y¯ij·) = (εijk − ε¯ij·)
I∑
i=1
J∑
j=1
K∑
k=1
(Yijk − Y¯ij·)2 =
I∑
i=1
J∑
j=1
K∑
k=1
(εijk − ε¯ij·)2
SSW =
I∑
i=1
J∑
j=1
K∑
k=1
(εijk − ε¯ij·)2
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E(SSW ) =
I∑
i=1
J∑
j=1
E{
K∑
k=1
(εijk − ε¯ij·)2}
=
I∑
i=1
J∑
j=1
(K − 1)σ2; since, εijk ∼ N(0, σ2)
= IJ(K − 1)σ2
σˆ2 =
SSW
IJ(K − 1)
Again, using the model (4.1), we have
Y¯ij· =µ+ αi + bij + ¯ij· (4.7)
Y¯i·· =µ+ αi + b¯i· + ¯i·· (4.8)
Subtracting equation (4.7) from equation (4.8), we get
(Y¯ij· − Y¯i··) = (bij − b¯i·) + (¯ij· − ¯i··)
I∑
i=1
J∑
j=1
K∑
k=1
(Y¯ij· − Y¯i··)2 =
I∑
i=1
J∑
j=1
K∑
k=1
{(bij − b¯i·) + (¯ij· − ¯i··)}2
SSR =
I∑
i=1
J∑
j=1
K∑
k=1
{(bij − b¯i·) + (¯ij· − ¯i··)}2
E(SSR) = K E
I∑
i=1
J∑
j=1
{(bij − b¯i·)2 + (¯ij· − ¯i··)2 (4.9)
+ 2 (bij − b¯i·)(¯ij· − ¯i··)}
the expectation of the cross product term vanishes since they are independent
of each other. Since bij ∼ N(0, τ2) and ¯ij· ∼ N(0, σ
2
K
), we get
E(SSR) = K I E[
J∑
j=1
(bij − b¯i·)2] + K I E[
J∑
j=1
(¯ij· − ¯i··)2]
E(SSR) = K I(J − 1)τ2 + K I(J − 1)σ
2
K
K I(J − 1)τˆ2 = SSR− I(J − 1)σˆ2
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τˆ2 =
SSR
K I(J − 1) −
σˆ2
K
Again, using the model (4.1), we get
Y¯i·· =µ+ αi + b¯i· + ¯i·· (4.10)
Y¯··· =µ+ α¯+ b¯+ ¯··· (4.11)
Subtracting equation (4.10) from equation (4.11), we get
Y¯i·· − Y¯··· =(αi − α¯) + (b¯i· − b¯) + (ε¯i·· − ε¯···)
I∑
i=1
J∑
j=1
K∑
k=1
(Y¯i·· − Y¯···)2 =
I∑
i=1
J∑
j=1
K∑
k=1
{(αi − α¯) + (b¯i· − b¯) + (ε¯i·· − ε¯···)}2
SSB = J K
I∑
i=1
{(αi − α¯) + (b¯i· − b¯) + (ε¯i·· − ε¯···)}2.
Since the bij ∼ N(0, τ2) and ¯ij· ∼ N(0, σ
2
K
), and, bij and ijk are indepen-
dent, we get
E(SSB) = J K{ E
I∑
i=1
(αi − α¯)2 + E
I∑
i=1
(b¯i· − b¯)2 + E
∑
i=1
(ε¯i·· − ε¯···)2}
= J K
I∑
i=1
(αi − α¯)2 + J K(I − 1)τ
2
J
+ J K(I − 1) σ
2
JK
E(SSB/(I − 1)) = J K
(I − 1)
I∑
i=1
(αi − α¯)2 + Kτ2 + σ2
SSB
(I − 1) = σˆ
2 +Kτˆ2 +
J K
(I − 1)
I∑
i=1
(αi − α¯)2
SSB
(I − 1) = σˆ
2 +Kτˆ2 +
J K
(I − 1)
I∑
i=1
ϕ(α); where ϕ(α) =
I∑
i=1
(αi − α¯)2
Under the H0, the sum of squares due to the treatments is,
SSB
(I − 1) = σˆ
2 +Kτˆ2
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The above statistical analysis is very elegantly presented in the following
anova table.
Source of Degree Sum of Mean Squares F-value p-value
variation of freedom Squares
Treatments (I − 1) SSB SSB/(I − 1) MSB
MSE
Meso groups I(J − 1) SSR SSR/I(J − 1) MSR
MSE
Residuals (N − I) SSE SSE/(N − I)
Total (N − 1) TSS
Table 4.1: ANOVA table for the Mixed Model.
When we apply the lme function in the dataset for k > 15, we get the
following estimations for the treatments A, B and C:
Treatments Estimates p− value
A 74.40× 104 6× 10−4
B 114.76× 104 1× 10−4
C 176.60× 104 0
Table 4.2: Estimates of treatments.
and, the standard deviation of random effects due to the meso groups and
error term are:
Standard deviation due to Standard deviation due to
meso groups (τˆ) error term (σˆ)
Estimates 18.39× 104 19.40× 104
Table 4.3: Estimates of random effects.
and the corresponding ANOVA table is given by,
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Source Numerator Denominator F− ratio p− value
degree of freedom degree of freedom
Intercept 1 81 354.83 <.0001
Treatment 2 6 20.896 < 0.002
Table 4.4: Mixed model ANOVA table.
If we look at the Table 3.3 and the Table 4.2 given by the model (3.1)
and model (4.1) respectively, we found that there are no differences in the
estimates of the treatments. Whereas, the residual standard error is signif-
icantly smaller in the model (4.1) than in the model (3.1). Because, in the
model (3.1), there is no effect of meso, and the εijk have to account for all
variability within each treatment. Therefore variance of εijk is large in this
model. In this model, the assumption of independence is violated because
the correlation is larger for observations coming from the same meso than for
two observations coming from different mesos. Therefore, we do not prefer
this model.
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Figure 4.1: Scatter plots of standardized residuals versus fitted
values for the model (4.1) by the treatment
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But, in the model (4.1), there accounts the meso effects and hence the
variance of εijk becomes smaller because it splits into the meso effects vari-
ance also. If we plot the standardized residuals versus fitted values by treat-
ments for the model (4.1), as shown in the Figure 4.1, we find that the
variability in the virus growth data is greater among the treatment B than
among the treatment A and C. Within each treatment, the variability seems
to be constant [Pinheiro and Bates, 2000].
To analysis different variances by treatments for the within-group error,
we use the varIdent function to model the heteroscedascity of the within-
group error [Pinheiro and Bates, 2000] and we get the following results.
Treatment A Treatment B Treatment C
1 1.523146 1.125218
Table 4.5: Parameter estimates of variance by treatments.
Figure 4.2 shows the heteroscedastic fit of model (4.1), that is, the re-
examining plots of standardized residuals versus fitted values by treatments.
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Figure 4.2: Scatter plots of standardized residuals versus fitted
values for the heteroscedastic fit of model (4.1) by treatments
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The standardized residuals in each treatment seem to have the same
variability [Pinheiro and Bates, 2000]. Table 4.1 explains that the standard
error for the treatment B and treatment C is about respectively 152% and
113% of that for the treatment A. If we apply an ANOVA test between the
model (4.1) and the heteroscedastic fit of model (4.1), we find there is no
significance between these two models. The output is given in the following
table.
Model df AIC BIC Loglik L.Ratio p−value
mod2 5 2399.51 2411.84 −1194.759
mod2.var 7 2398.31 2415.57 −1192.15 5.20 0.0741
Table 4.6: ANOVA table of model (4.1) and it‘s heteroscedastic
fitted model.
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5
Nonlinear Mixed Effects Model
In our previous chapters, we analysed the dataset for k > 15 and found
significant differences between the treatment effects.
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Figure 5.1: Plot for individual random meso groups of three dif-
ferent treatments
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In this chapter, we look the whole dataset, that is for k = 1, 2, · · · , 25
and try to find out the best fitted model for the dataset. As shown in
Figure 5.1, if we plot a graph of the response variable (number of virus)
versus the time period (day) for the random individual meso groups, we
find a individual growth curve for each meso group. Where we can see for
each meso group, the curve is approximately stationary for some begining
days of experiment and gradually starts increasing and accelerates over the
time period. Finally, it reaches at its maximum height and keeps this level
approximately stationary to the end of time period. Generally, such a type of
the curve nature is shown by the sigmoid curve which exhibit a progression
from small beginnings that accelerates and approaches a climax over time.
There are many functions that displays a sigmoid form [Wikipedia/Sigmoid].
A logistic curve is a common sigmoid curve and in such a curve the initial
stage of growth is approximately exponential; then, as saturation begins, the
growth slows, and at maturity, growth stops [Wikipedia/Logistic].
0
y
x
1
2
y = 1
2
3
+
3
-
Figure 5.2: The simple logistic model showing the parameters φ1,
the horizontal asymptote as x → ∞; φ2, the value of x for which
y = φ1/2; and φ3, a scale parameter on the x-axis.
Figure 5.2 shows a logistic curve with three parameters φ1, φ2 and, φ3
where φ1 represents the maximum growth when the curve is at maturity;
φ2 represents the point when the slow down begins or the point where the
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growth reaches half of its maximum and; φ3 represents the rate of the growth
at x = φ2. Which is approximately equivalent to the nature of the meso curve
given by our dataset where at first phase, there is slow increasing of virus,
then at second phase it gradually starts increasing, and accelarates and at
third phase it becomes mature and keeps approximately the similar phase
level over the time period. Such a logistic curve is well explained by the
logistic growth model and is given by
yjk = f(φ, x) + jk =
φ1
1 + e−(x−φ2)/φ3
+ jk (5.1)
[Pinheiro and Bates, 2000] for j = 1, 2, · · · , J and k = 1, 2, · · · ,K with
φ1 : the asymptote, gives the maximum height of the curve that
reaches over the time. When φ3 > 0 then φ1 is the horizontal
asymptote as x→∞ and 0 is the horizontal asymptote as
x→ −∞.
φ2 : the inflex, explains time when the curve reaches half of its
maximum level, that is, when y = φ1/2.
φ3 : the scale, gives the rate of change at x = φ2
yjk : The growth pattern at time x.
jk : within-group error associated with yjk or the additive noise
of the model and is normal.
f(φ, x) : average response for group j at time x, conditional on φ1, φ2, φ3.
The above model (5.1) is linear in parameter φ1 but nonlinear in param-
eters φ2 and φ3. So it is a nonlinear model.
where y = yjk =
1
2
φ1 when x = φ2 such that yjk = f(φ, x) =
φ1
1 + e−(φ2−φ2)/φ3
=
φ1
1 + e−0
=
1
2
φ1, which is half of the asymptote height and is numerically sta-
ble point for study of the curve nature. Similarly, if this point shifts from
φ2 to φ2 ± φ3, i.e., when x = φ2 ± φ3, we get f(φ, x) = φ1
1 + e−1
' 34φ1 and
f(φ, x) =
φ1
1 + e1
' 14φ1. Now, the rate of change (slope) of the asymptote
with respect to the X−axis is given by dy
dx
such that
dy
dx
= f ′(φ, x) =
d
dx
[
φ1
1 + e−(x−φ2)/φ3
]
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= φ1
[
d(1 + e−(x−φ2)/φ3)−1
d(1 + e−(x−φ2)/φ3)
· d(1 + e
−(x−φ2)/φ3)
dx
]
= φ1
[
−1 (1 + e−(x−φ2)/φ3)−2 · −1
φ3
e−(x−φ2)/φ3
]
=
1
φ3
· φ1
1 + e−(x−φ2)/φ3
· e
−(x−φ2)/φ3
1 + e−(x−φ2)/φ3
=
1
φ3
· y(x) · e
−(x−φ2)/φ3
1 + e−(x−φ2)/φ3
when x = φ2,[
dy
dx
]
x=φ2
= f ′(φ, x = φ2) =
1
φ3
· φ1
2
· e
−0
1 + e−0
=
1
4
φ1
φ3
That is, the slope of curve at x = φ2 is
φ1
4 φ3
and, it depends on φ3.
Therefore the slope decreases as φ3 increases or vice versa.
In our case, since there are both fixed and random effects, it becomes a
nonlinear mixed effects models with j = 1, 2, · · · , 9 and k = 1, 2, · · · , 25. So
for the given dataset, we define the parameters as
φ =
φ1jφ2j
φ3j
 for j = 1, 2, · · · , 9.
such that φ1j = β
(i)
1 + b1j φ1j = β
(i)
2 + b2j φ1j = β
(i)
3 + b3j
where β(i)1 , β
(i)
2 , β
(i)
3 are the fixed growth parameters for three treatments, i =
A,B,C. That is, for treatments A, B and C, the fixed growth parameter β =[
β
(A)
1 β
(A)
2 β
(A)
3 β
(B)
1 β
(B)
2 β
(B)
3 β
(C)
1 β
(C)
2 β
(C)
3
]T
and, b =
b1jb2j
b3j
 is random
parameter due to the meso group for j = 1, 2, · · · , 9. It can be summarized
as
φj = Djβ + bj (5.2)
where [Dj ](3×9) is a design matrix [Pinheiro and Bates, February 25, 2005]
such that
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when j = 1, 2, 3 then
Dj =
1 0 0 0 0 0 0 0 00 1 0 0 0 0 0 0 0
0 0 1 0 0 0 0 0 0

when j = 4, 5, 6 then
Dj =
0 0 0 1 0 0 0 0 00 0 0 0 1 0 0 0 0
0 0 0 0 0 1 0 0 0

when j = 7, 8, 9 then
Dj =
0 0 0 0 0 0 1 0 00 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 1

5.1 Parameter Estimation and Selection
Treatment Meso Estimation of Parameters φ1, φ2, φ3
(i) (j) Fixed effects (β) Random effects (bj)
1 β(A)1 β
(A)
2 β
(A)
3 b11 b21 b31
A 2 " " " b12 b22 b32
3 " " " b13 b23 b33
4 β(B)1 β
(B)
2 β
(B)
3 b14 b24 b34
B 5 " " " b15 b25 b35
6 " " " b16 b26 b36
7 β(C)1 β
(C)
2 β
(C)
3 b17 b27 b37
C 8 " " " b18 b28 b38
9 " " " b19 b29 b39
Table 5.1: Estimations of Parmameters φ1, φ2, φ3 for Nonlinear
Mixed Model.
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When we begin to estimate the parameters for each meso by using the
relation (5.2), we get three estimates of fixed effects and three estimates
of random effects for the parameters φ1, φ2, φ3 of an an individual meso.
From the table 5.1, it is clearly seen that the fixed effects are similar for
mesos in each treatment, that is, the fixed effects are different by treatment
and, the random effects are totally different for different mesos. Hence, the
model (5.1) gives both fixed effects and random effects for our dataset. We
build up several models to find out a best fitted model by determining the
characterstics of both fixed and the random effects of a given model (5.1). We
describe procedures based on information statistics for comparing different
structures of random effects component. These procedures are determining
which parameters in the model should be mixed effects and which should be
purely fixed effects. Most of the methods applied in this study, are based on
nonlinear mixed effects methods and classes for S-plus [Pinheiro and Bates,
2000] in R. Table 5.2 gives an individual estimation of the fixed and the
random effects for parameters φ1, φ2, φ3 for each meso where we can see that
all three estimates seem to vary with individual.
Meso φˆ1 φˆ2 φˆ3
1 79.49× 104 11.94 2.79
2 86.61× 104 13.06 1.31
3 116.92× 104 20.15 4.27
4 147.83× 104 11.00 1.66
5 110.54× 104 12.07 1.74
6 86.81× 104 10.19 1.50
7 176.34× 104 10.48 1.35
8 173.93× 104 11.32 2.03
9 180.17× 104 12.28 1.90
Residual standard error = 17.11× 104
Table 5.2: Estimations of parmameters φ1, φ2, φ3 for individual
meso.
33
The plot of the individual confidence intervals for the estimates given in
the Table 5.2 is shown in Figure 5.3.
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Figure 5.3: Ninety-five percent confidence intervals for an individ-
ual meso for the three different parameters of given model
These confidence intervals, as shown in the Figure 5.3, indicate that the
parameter asymptote φ1 has the greatest inter-individual variability, followed
by the parameter inflex φ2 whereas the parameter scale φ3 has not such a
variability with individual, as all the associated confidence intervals overlap.
These results suggest that φ1 and φ2 can be treated as mixed effects and φ3
as a purely fixed effect [Pinheiro and Bates, 2000]. We test it again by the
nlme method also.
We now consider the nlme function to find more adequate result about
the random effect and the fixed effect parameters for the model 5.1. For
this purpose, we start a model with random effects for all parameters and
then examine the fitted object to decide which, if any, of the random effects
can be eliminated from the model. Since bj are assumed to be independent
and normal with mean 0 and variance-covariance matrix Ψ, the number
of parameters to estimate will increase with the square of the number of
random effects. In such cases where the number of random effects is large
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relative to the number of individuals, it is generally recommended to use
a diagonal variance-covariance matrix Ψ initially, to prevent convergence
problems with an overparametrized model [Pinheiro and Bates, 2000]. We
apply this approch in our dataset and we get following information.
Standard deviation of Estimation of Fixed effects
Random effects (βˆ)
φ1 φ2 φ3 Residual φˆ1 φˆ2 φˆ3
42.48× 104 1.74 0.003 17.08× 104 123.90× 104 12.1 1.8
Standard Error 14.429× 104 0.62 0.14
Table 5.3: Estimation of fixed effects and the standard deviation
of random effects for parameters φ1, φ2, φ3 given by the model 4.
The small estimated value of the standard deviation of the parameter
scale φ3 suggests us that this term could not be implementated as a random
effect parameter in our model. Whereas the remaining estimated standard
deviation suggest that other radom effects must be kept in our model. To
assure these facts, we use ANOVA test between the model that contains the
parameter inflex φ3 random effect (model 4) and the model that does not
contain the parameter scale φ3 random effect (model 5) [Pinheiro and Bates,
2000]. We get the following outputs.
Model DF AIC BIC LogLik Test L.Ratio p−value
Model 4 7 5650.18 5673.51 −2818.09
Model 5 6 5648.18 5668.58 −2818.09 4 Vs 5 0.0002 0.99
Table 5.4: Comparison of model 4 with model 5 using an ANOVA
The two fitted models, in the table 5.4, give nearly identical log-likelihoods
with higher p− value, confirming us that scale φ3 can be treated as a purely
fixed effect [Pinheiro and Bates, 2000]. Generally, if the fixed effects are
unknown for the treatments then it is calculated by providing the start-
ing values for parameters φ1, φ2, φ3 [Pinheiro and Bates, 2000]. We remove
unnecessary fixed effect parameters by using an ANOVA test of different
models with different number of fixed effects estimates. The Following Ta-
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ble 5.5 gives the different models with their corresponding number of fixed
effects and random effects parameters.
Mo- No. of Random Fixed AIC BIC Log-Lik.
del para- parameters parameters
meters
4 7 b1, b2, b3 β1, β2, β3 5650.183 5673.512 -2818.091
5 6 b1, b2 β1, β2, β3 5648.183 5668.179 -2818.091
6 5 b1 β1, β2, β3 5657.688 5674.351 -2823.844
7 13 b1, b2, b3 β
(A)
1 , β
(B)
1 , β
(C)
1 5634.924 5678.249 -2804.462
β
(A)
2 , β
(B)
2 , β
(C)
2
β
(A)
3 , β
(B)
3 , β
(C)
3
8 12 b1, b2 β
(A)
1 , β
(B)
1 , β
(C)
1 5632.924 5672.917 -2804.462
β
(A)
2 , β
(B)
2 , β
(C)
2
β
(A)
3 , β
(B)
3 , β
(C)
3
9 10 b1, b2 β
(A)
1 , β
(B)
1 , β
(C)
1 5630.621 5663.948 -2805.310
β
(A)
2 , β
(B)
2 , β
(C)
2
β3
10 8 b1, b2 β
(A)
1 , β
(B)
1 , β
(C)
1 5633.427 5660.088 -2808.713
β2, β3
11 11 b1 β
(A)
1 , β
(B)
1 , β
(C)
1 5637.303 5673.963 -2807.651
β
(A)
2 , β
(B)
2 , β
(C)
2
β
(A)
3 , β
(B)
3 , β
(C)
3
12 9 b1 β
(A)
1 , β
(B)
1 , β
(C)
1 5635.613 5665.608 -2808.807
β
(A)
2 , β
(B)
2 , β
(C)
2
β3
13 7 b1 β
(A)
1 , β
(B)
1 , β
(C)
1 5642.773 5666.102 -2814.386
β2, β3
14 6 b1, b3 β1, β2, β3 5659.688 5679.685 -2823.844
Table 5.5: Different models with different number of estimates of
parameters with AIC, BIC and log-likelihood.
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Here, the values of Akaike Information Criterian (AIC) and Baysian In-
formation Criterion (BIC) are the model comparison criteria, and evaluated
as
AIC = −2logLik + 2npar
BIC = −2logLik + nparlog(N)
where npar denotes the number of parameters in the model and N the total
number of observations used to fit the model [Pinheiro and Bates, 2000].
5.2 Model Selection
The best fitted model is selected with the lowest Bayesian Information
Criterion abbreviated by BIC , under the criterion "smaller is better" [Pin-
heiro and Bates, 2000]. In our case, when we analysis the output given by
the Table 5.5, we can see that the model 10 has the lowest BIC value with
the least numbers of estimates. So, in our study we prefer the model 10 as
a best fitted model and it has mixed effects in the parameter asymptote φ1
and the parameter inflex φ2. But the parameter scale φ3 has purely a fixed
effect. All three parameters details for three treatments are presented in the
Table 5.6 below.
Treatments Parameters
(i) φ1 φ2 φ3
For i = A; j = 1, 2, 3. β(A)1 + b1j β2 + b2j β3
For i = B; j = 4, 5, 6. β(B)1 + b1j β2 + b2j β3
For i = C; j = 7, 8, 9. β(C)1 + b1j β2 + b2j β3
Residual = 17.09× 104
Table 5.6: Parameter detail information for all treatments
From above Table 5.6, we can say that the selected model has
• significance in the parameter asymptote φ1 for all three treatments due
to the variability in the fixed effects and the random effects and hence
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the parameter asymptote has a different mixed effects for different
treatments.
• significance in the parameter inflex φ2 for all three treatments due to
the variability in the random effects. But it has a common fixed effect
for all three treatments. Hence it has also different mixed effects for
all three treatments.
• an uniform fixed effect parameter φ3 for all three treatments and hence
it has a purely fixed effect.
• a lower Residual standard error.
For further detail information, a summary of model 10 is presented below.
Nonlinear mixed-effects model fit by maximum likelihood
Model: virus ~ SSlogis(day, asymp, inflex, scale)
Data: hfvgr
AIC BIC logLik
5633.427 5660.088 -2808.713
Random effects:
Formula: list(asymp ~ 1, inflex ~ 1)
Level: meso
Structure: Diagonal
asymp.(Intercept) inflex Residual
StdDev: 141837.4 1.709932 170922.8
Fixed effects: list(asymp ~ treatment, inflex + scale ~ 1)
Value Std.Error DF t-value p-value
asymp.(Intercept) 790672.1 91029.62 194 8.685877 0.0000
asymp.treatmentB 367716.9 126780.81 194 2.900414 0.0042
asymp.treatmentC 974723.5 127015.21 194 7.674069 0.0000
inflex 12.1 0.61 194 19.725391 0.0000
scale 1.8 0.14 194 12.144918 0.0000
Correlation:
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as.(I) asym.B asym.C inflex
asymp.treatmentB -0.711
asymp.treatmentC -0.707 0.510
inflex 0.057 -0.016 -0.020
scale 0.084 0.006 0.042 0.067
Standardized Within-Group Residuals:
Min Q1 Med Q3 Max
-3.5625885 -0.4235803 0.1741952 0.5227076 3.2616369
Number of Observations: 207
Number of Groups: 9
5.3 Heteroscedascity Model
If we plot a graph of standardized residuals versus fitted values by the
time period, as shown in Figure 5.4, we can see that there is lower variability
at the beginning of the experiment.
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Figure 5.4: Scatter plot of Standardized residuals versus fitted
values for model 10
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But as time increases the variability also increases, and before ending the
experiment, there exists a greater variability. Standardized residual is the
residual divided by its standard deviation that is
Standardized residual k =
Residual k
Standard Deviation of Residual k
and the residual data of the simple linear regression model is the difference
between the observed data of the dependent variable Y and the fitted values
Yˆ such that
Residual = Y − Yˆ
[Yau, 2009 - 2011].
Such type of residual variability that increases with increment of time
period, explains a heteroscedascity in a given model and such kinds of vari-
ance structure of the within-group errors are modelled by variance functions
using covariates. The general variance function model for the within-group
errors in the model is defined as
V ar(ijk|bj) = σ2g2(µijk,υijk,γ) (5.3)
where, i = 1 · · · I j = 1, · · · , J, k = 1, · · · ,K. The above variance func-
tion model (5.3) is applicable only when the within-group errors and random
effects are assumed to be dependent. But in our case, we assume that the
within-group errors are independent of the random effects, and the variance
function model becomes as
V ar(ijk) ' σ2g2(µˆijk,υijk,γ) (5.4)
Where, the expected values µijk = E[yijk|bj ] are replaced by their BLUPs
µˆijk = x
T
ijkβ+ z
T
ijkbˆj such that xijk and zijk are denoting the j
th rows of Xi
and Zi. υ is a vector of variance covariates, γ is a vector of variance param-
eters and g(.) is the variance function, assumed continuous in γ [Pinheiro
and Bates, 2000]. But in our case, from the Figure 5.4, it seems that the
within-group variability are increasing as growth of virus increasing. There-
fore, we assume that the within-group variability are increasing with some
power of the absolute value of covariate, i.e. with some power of the fitted
values. So, we can write,
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V ar(ijk) = σ
2|yˆijk|2γ
where  ∼ N(0, σ2), yˆijk = variance covariate (the fitted value) and γ is
the variance parameter. The nlme library provides a several varFunc classes
[Pinheiro and Bates, 2000]. In our model, we prefer varPower function to
model the heteroscedascity. Following table gives the different heteroscedasc-
ity models with different forms.
Model Variance AIC BIC Log Residual
parameters -likelihood
10.var γ 5593.03 5623.025 -2787.515 5.169× 103
10.var1 γ1, γ2, γ3 5596.244 5632.904 -2787.122 25.764× 103
10.var2 γ1, γ2, · · · , γ9 5598.687 5655.343 -2782.344 25.982× 103
Table 5.7: Different heteroscedascity models for the best ho-
mogenous model with variance parameters, AIC, BIC and log-
likelihood.
Fitted values
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Figure 5.5: Scatter plot of Standardized residuals versus fitted
values for the heteroscedascity model.
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If we analyze the above Table 5.7 under the criterion of smaller BIC,
we prefer the model “10.var” as the best heteroscedascity model with single
variance parameter for our dataset. That is, we have, σ(ijk) = σˆ(yˆijk)0.267.
The corresponding residual plot of the heteroscedascity model is shown above
in the Figure 5.5.
Model DF BIC LogLik Test L.Ratio p−value
10 8 5660.08 −2808.71
10.var 9 5623.025 −2787.51 10 Vs 10.var 42.40 <.0001
Table 5.8: Comparison of the model 10 and the model 10.var using
an ANOVA
The very small p−value of the likelihood ratio statistic in the above
ANOVA Table 5.8 confirms that the heteroscedascity model explains the
data significantly better than the homoscedastic model [Pinheiro and Bates,
2000]. Figure 5.5 shows the standardized residuals have approximately the
same variability. A plot of heteroscedascity fit model for the treatment effect
predictions (fixed effect), meso group predictions (random effect) and the
observed values, is shown in figure 5.6 (in the next page.)
42
day 
v
ir
u
s
 
0
500000
1000000
1500000
2000000
0 5 10 15 20 25
l l l ll
l
l
l
lllll
l
l
ll
l
l
ll
ll
3
l l
l lllll
ll
l
l
l
l
l
l
l
l
l
l
l
ll
2
0 5 10 15 20 25
l l l
ll
ll
l
lll
l
l
l
l
l
lll
l
l
l
l
1
l l l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
ll
l
ll
5
l l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
6
0
500000
1000000
1500000
2000000
l l l
l
ll
l
l
l
l
l
ll
lll
l
l
l
l
l
l
l
4
0
500000
1000000
1500000
2000000
l l l
lll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
7
0 5 10 15 20 25
l l l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
8
l l l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
9
fixed meso
Figure 5.6: The treatment effect predictions (fixed), meso group
predictions (random), and observed values for the heteroscedascity
fit model.
43
6
Conclusions
The fixed-effects linear model, the linear mixed-effects model and the
nonlinear mixed-effects, discussed in above chapters give us the uniform
conclusion that there is significant difference in the treatment effects. But
the nonlinear mixed-effects model, the logistic growth model, explained by
the homogenous “model 10" not only describes the significant difference of
treatments but it also tells us that the growth levels of virus under these
treatments are affected by the mixed-effects and fixed effects i.e., the best
fitted homogenous model 10 defines the non-linear model (5.1), i.e.,
yjk = f(φ, x) + jk =
φ1
1 + e−(x−φ2)/φ3
+ jk
[Pinheiro and Bates, 2000] as a mixed-effects non-linear model where the
parameter asymptote φ1 has the mixed-effects such that it has three different
fixed effects for three different treatments and different random effects for
different mesos. Similarly, the parameter inflex φ2 also has the mixed-effect
such that it has uniform fixed effects for all treatments and different random
effects for the different mesos. Whereas the parameter scale φ3 has the fixed
effects only such that it has uniform fixed effects for all three treatments.
Therefore, we write, for j = 1, 2, 3.,
φA =
φ
(A)
1j
φ
(A)
2j
φ
(A)
3j
 =
β
(A)
1
β
(A)
2
β
(A)
3
+
b
(A)
1j
b
(A)
2j
0

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for j = 4, 5, 6.,
φ(B) =
φ
(B)
1j
φ
(B)
2j
φ
(B)
3j
 =
β
(B)
1
β
(B)
2
β
(B)
3
+
b
(B)
1j
b
(B)
2j
0

and, for j = 7, 8, 9.,
φ(C) =
φ
(C)
1j
φ
(C)
2j
φ
(C)
3j
 =
β
(C)
1
β
(C)
2
β
(C)
3
+
b
(C)
1j
b
(C)
2j
0

Where
β
(A)
2 = β
(B)
2 = β
(C)
2 ,
β
(A)
3 = β
(B)
3 = β
(C)
3
and,
b
(A)
3j = b
(B)
3j = b
(C)
3j = 0
Following Table 6.1 gives the detail information about the three parameters
for the model 10.
Treatment Meso Estimated value of Parameters
(i) (j) Asymptote (φˆ1) Inflex (φˆ2) Scale (φˆ3)
(β1) (b1) (β2) (b2) (β3)
1 79.06× 104 −2.40× 104 1.2 0.041 1.75
A 2 79.06× 104 7.24× 104 1.2 0.072 1.75
(intercept) 3 79.06× 104 −4.84× 104 1.2 4.039 1.75
4 36.77× 104 28.89× 104 1.2 −1.133 1.75
B 5 36.77× 104 −4.53× 104 1.2 −1.017 1.75
6 36.77× 104 −24.35× 104 1.2 −1.511 1.75
7 97.47× 104 2.41× 104 1.2 −1.545 1.75
C 8 97.47× 104 −4.41× 104 1.2 −0.811 1.75
9 97.47× 104 1.99× 104 1.2 0.175 1.75
Table 6.1: Estimated values of Parmameters φ1, φ2, φ3 for the
model 10.
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We also get the following tables for the homogenous model 10.
Estimates for the fixed effects
for φ1 : βˆ1
(A)
βˆ
(B)
1 βˆ
(C)
1
79.06× 104 36.77× 104 97.47× 104
for φ2 : βˆ
(A)
2 = βˆ
(B)
2 = βˆ
(C)
2 = 12.1
for φ3 : βˆ
(A)
3 = βˆ
(B)
3 = βˆ
(C)
3 = 1.8
Table 6.2: The estimated values of the fixed effects and their corre-
sponding standard errors for treatments A,B and, C in the model
10
Standard error for the estimates of the fixed effects
for φ1 : βˆ1
(A)
βˆ
(B)
1 βˆ
(C)
1
9.10× 104 12.68× 104 12.70× 104
for φ2 : βˆ
(A)
2 = βˆ
(B)
2 = βˆ
(C)
2 = 0.61
for φ3 : βˆ
(A)
3 = βˆ
(B)
3 = βˆ
(C)
3 = 0.14
Table 6.3: The standard error of the estimates of the fixed effects
for treatments A,B and, C in the model 10
Standard deviation of the random effects
for φ1 : SD (b
(A)
1j ) = SD (b
(B)
1j ) = SD (b
(C)
1j ) = 14.18× 104
for φ2 : SD (b
(A)
2j ) = SD (b
(B)
2j ) = SD (b
(C)
2j ) = 1.7
for φ3 : SD (b
(A)
3j ) = SD (b
(B)
3j ) = SD (b
(C)
3j ) = 0
for Residual: 17.09× 104
Table 6.4: The standard deviation of the random effects for treat-
ments A,B and, C in the model 10
The best fitted model for our dataset is selected on the basis of the
information criterion of BIC and loglikelihood values. The heteroscedasticity
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fit model is also applied to minimize the with-in group variability in the best
fitted model. The summary of heteroscedascity fit model is given below
Nonlinear mixed-effects model fit by maximum likelihood
Model: virus ~ SSlogis(day, asymp, inflex, scale)
Data: hfvgr
AIC BIC logLik
5593.03 5623.025 -2787.515
Random effects:
Formula: list(asymp ~ 1, inflex ~ 1)
Level: meso
Structure: Diagonal
asymp.(Intercept) inflex Residual
StdDev: 151059 0.6768236 5169.563
Variance function:
Structure: Power of variance covariate
Formula: ~fitted(.)
Parameter estimates:
power: 0.2666935
Fixed effects: list(asymp ~ treatment, inflex + scale ~ 1)
Value Std.Error DF t-value p-value
asymp.(Intercept) 734895.8 95534.02 194 7.69250 0.000
asymp.treatmentB 454212.7 135327.07 194 3.35641 0.001
asymp.treatmentC 1081529.3 137781.29 194 7.84961 0.000
inflex 11.7 0.34 194 34.29696 0.000
scale 2.3 0.17 194 13.60285 0.000
Correlation:
as.(I) asym.B asym.C inflex
asymp.treatmentB -0.690
asymp.treatmentC -0.672 0.485
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inflex 0.116 0.019 0.045
scale 0.097 0.036 0.092 0.369
Standardized Within-Group Residuals:
Min Q1 Med Q3 Max
-2.7097857 -0.5248593 0.1187200 0.8288833 2.4591550
Number of Observations: 207
Number of Groups: 9
we can see that the residual error is the least in the heteroscedascity model,
indicating us that it fits the best for our dataset.
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A
R code
A.1 Grouping and selecting data after day 15
hfvgr=groupedData(virus~day|meso, data=hfv)
hfvgr=subset(hfvgr, day>15)
A.2 Applying linear model and linear mixed effect
model for the dataset when K>15
mod1=lm(virus~treatment, data=hfvgr)
summary(mod1)
anova(mod1)
mod2=lme(virus~treatment, random=~1|meso, data=hfvgr)
summary(mod2)
anova(mod2)
A.3 Applying nonlinear mixed effect model (nlme)
for the whole dataset
library(nlme)
hfv=read.table("hfv.dat",header=T)
hfvgr=groupedData(virus~day|meso, data=hfv)
form=virus~SSlogis(day,asymp,inflex,scale)
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A.4 Selecting the model by applying different func-
tions
model 1=nls(form,data=hfvgr)
summary(model 1)
model 2=nlsList(virus~SSlogis(day,asymp,inflex,scale),
data=hfvgr)
summary(model 2)
plot(intervals(model 2),layout=c(3,1),main="Model 2 :
Intervals(nlsList)")
model 3=nlsList(virus~SSlogis(I(day-12),asymp,inflex,scale),
data=hfvgr)
summary(model 3)
model 4=nlme(model 2,random=pdDiag(asymp+inflex+scale~1))
summary(model 4)
anova(model 4)
model 5=nlme(model 2,random=pdDiag(asymp+inflex~1))
summary(model 5)
anova(model 4,model 5)
model 6=nlme(model 2,random=pdDiag(asymp~1))
summary(model 6)
anova(model 4,model 5,model 6)
options(contrasts=c("contr.treatment","contr.poly"))
hfvfix=fixef(model 4)
hfvfix
model 7=update(model 4, fixed=list(asymp+inflex+scale
~treatment),start=c(hfvfix[1],0,0,hfvfix[2],0,0,
hfvfix[3],0,0))
summary(model 7)
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anova(model 7)
model 8=update(model 5, fixed=list(asymp+inflex+scale
~treatment),start=c(hfvfix[1],0,0,hfvfix[2],0,0,
hfvfix[3],0,0))
summary(model 8)
model 9=update(model 8, fixed=list(asymp+inflex~treatment,
scale~1),start=c(hfvfix[1],0,0,hfvfix[2],0,0,hfvfix[3]))
summary(model 9)
model 10=update(model 9, fixed=list(asymp~treatment,
inflex+scale~1),start=c(hfvfix[1],0,0,hfvfix[2],
hfvfix[3]))
summary(model 10)
plot(augPred(model 10,level=0:1),main="Model 10 :
(R~A+I, T~A)",layout=c(3,3))
model 11=update(model 6, fixed=list(asymp+inflex+scale
~treatment),start=c(hfvfix[1],0,0,hfvfix[2],0,0,
hfvfix[3],0,0))
summary(model 11)
model 12=update(model 11, fixed=list(asymp+inflex~
treatment,scale~1),start=c(hfvfix[1],0,0,hfvfix[2],0,0,
hfvfix[3]))
summary(model 12)
model 13=update(model 12, fixed=list(asymp~treatment,
inflex+scale~1),start=c(hfvfix[1],0,0,hfvfix[2],hfvfix[3]))
summary(model 13)
model 14=nlme(model 2,random=pdDiag(asymp+scale~1),
fixed=list(asymp+inflex+scale~treatment),start=c(hfvfix
[1],0,0,hfvfix[2],0,0,hfvfix[3],0,0))
summary(model 14)
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A.5 Selecting and ploting the best homogenous model
data.frame(model,aic,bic,loglik)
min(aic)
min(bic)
min(loglik)
plot(augPred(model 10,level=0:1),main="Model 10 :
(R~A+I, T~A)",layout=c(3,3))
plot(model 10,resid(.,type="p")~fitted(.),
main="Model 10 : Fitted Vs Residuals wrt days")
A.6 Selecting and plotting for a heteroscedascity
model
model 10.var=update(model 10,weights=varPower(form=~fitted(.)))
summary(model 10.var)#gives lower bic value.
model 10.var1=update(model 10,weights=varPower(form=~fitted(.)
|treatment))
summary(model 10.var1)
model 10.var2=update(model 10,weights=varPower(form=~fitted(.)
|meso*treatment))
summary(model 10.var2)
data.frame(model,aic.var,bic.var,loglik.var)
min(aic.var)
min(bic.var)
min(loglik.var)
plot(model 10.var)
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